Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 9,546 matching trials from the live ClinicalTrials.gov search.

Filters: Birmingham, Alabama Clear all

Conditions: Pain, Postoperative
Interventions: PMI-150 (intranasal ketamine), Placebo; Drug
Lead sponsor: Hospira, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 16
States / cities: Birmingham, Alabama • Florence, Alabama • Sheffield, Alabama + 13 more

Conditions: Irritable Bowel Syndrome With Constipation, Chronic Constipation
Interventions: Linaclotide; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 116
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 106 more

Conditions: Car Seat Installation
Interventions: interactive virtual presence, live technician; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 15 Years and older
Enrollment: 1,498 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Bacterial Vaginosis
Interventions: SYM-1219, Placebo; Drug
Lead sponsor: Symbiomix Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 16
States / cities: Birmingham, Alabama • San Diego, California • Clearwater, Florida + 13 more

Conditions: Multiple Myeloma
Interventions: Bortezomib, Dexamethasone, Melphalan, Prednisone, Thalidomide; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 234
States / cities: Birmingham, Alabama • Casa Grande, Arizona • Sedona, Arizona + 205 more

Conditions: Systemic Lupus Erythematosus
Interventions: A-623, Placebo Comparator; Drug · Other
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 14
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 11 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Ibrutinib, Obinutuzumab, Observation Activity, Venetoclax; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 65 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 857
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 555 more

Conditions: Systemic Lupus Erythematosus
Interventions: Belimumab, Rituximab, Rituximab-placebo, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 28
States / cities: Birmingham, Alabama • La Mesa, California • San Leandro, California + 22 more

Conditions: Non-small Cell Lung Cancer
Interventions: Telisotuzumab vedotin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 56
States / cities: Mobile, Alabama • Phoenix, Arizona • Springdale, Arkansas + 49 more

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Nystatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Birmingham, Alabama • Princeton, New Jersey

Conditions: Vasomotor Symptoms
Interventions: desvenlafaxine succinate (DVS) SR, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 2,186 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 102
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 86 more

Conditions: Body Composition, Energy Balance, Metabolism
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 3 Years to 7 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
Interventions: Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib, Utomilumab, Liposomal Doxorubicin, Sacituzumab Govitecan; Biological · Drug
Lead sponsor: Laura Huppert, MD, BA; Other
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more

Conditions: Cystic Fibrosis
Interventions: Behavioral Counseling and Exercise; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cystic Fibrosis
Interventions: Iontophoresis sweat test; Device
Lead sponsor: Polychrome Medical, Inc.; Industry
Eligibility: Not listed
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Birmingham, Alabama • Chicago, Illinois • Ann Arbor, Michigan + 3 more

Conditions: Hip Fractures, Muscle Atrophy
Interventions: Blood Flow Restriction with Delfi Tourniquet System Cuff, Routine Post-operative Physical Therapy; Device · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 65 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Schizophrenia
Interventions: placebo, Ziprasidone oral capsules; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 46
States / cities: Birmingham, Alabama • San Diego, California • Stanford, California + 34 more

Conditions: Epilepsy, Idiopathic Generalized Epilepsy, Generalized Tonic Clonic Seizure
Interventions: Responsive stimulation, Sham stimulation; Device
Lead sponsor: NeuroPace; Industry
Eligibility: 12 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 18 more

Conditions: Persistent Pulmonary Hypertension of the Newborn
Interventions: 1 dose of sildenafil; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Up to 364 Days
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 9
States / cities: Birmingham, Alabama • Indianapolis, Indiana • Louisville, Kentucky + 6 more

Conditions: Atrial Fibrillation
Interventions: Azimilide Dihydrochloride, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 88
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 79 more

Conditions: Lymphoma
Interventions: aldesleukin, filgrastim, recombinant interferon gamma, carmustine, cyclosporine, cytarabine, etoposide, melphalan, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 53 more

Conditions: Iron Deficiency Anemia, Pregnancy
Interventions: Ferric derisomaltose, Ferrous sulfate; Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Miami, Florida • Ann Arbor, Michigan + 4 more

Conditions: Multiple Myeloma
Interventions: bb2121, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Ixazomib, Lenalidomide, Carfilzomib, Elotuzumab; Biological · Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 36
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 26 more

Conditions: Myelodysplastic Syndromes
Interventions: TLK199 HCl Liposomes for Injection; Drug
Lead sponsor: Telik; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 6 more

Search by objective public record fields.

Safety and Efficacy of Repeated Doses of PMI-150 (Intranasal Ketamine) in Acute Post-operative Pain Following Orthopedic Surgery

An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Using Interactive Virtual Presence to Remotely Assist Parents With Child Restraint Installations

A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis

Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone

PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes

Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women

Bad Genes or Genes Behaving Badly

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Feasibility of a New Model for Exercise Prescription in Cystic Fibrosis

A Multi-Center Study of the CF Quantum® Sweat Test System

The Role of Blood Flow Restriction Therapy in Postoperative Elderly Patients With Hip Fracture

Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia

RNS System NAUTILUS Study

Pharmacokinetics of Sildenafil in Premature Infants

Efficacy and Safety of Azimilide in the Prophylactic Treatment of Patients With Atrial Fibrillation.

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome